Clinical Trial Update: Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating two doses of seladelpar (MBX-8025) for primary biliary cholangitis was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• Seladelpar (seladelpar)

Snippet

Sponsor: Gilead Sciences | Conditions: Primary Biliary Cirrhosis (PBC) | Phase 2 | Status: TERMINATED | Results posted: 2025-02-25